Skip to content
Open access

A background-suppressed CRISPR/Cas13a-HRCA biosensor for ultrasensitive miR-137 detection toward differential screening of Alzheimer's disease.

Oct 2026 · Talanta: The International Journal of Pure and Applied Analytical Chemistry · Vol 314, pp. 130886 · 0 citations · 30 references
Medicine

Abstract

Alzheimer's disease (AD) is associated with pathological changes that can occur years before the onset of clinical symptoms, highlighting the importance of sensitive biomarker detection for early diagnosis. Here, we developed a fluorescence biosensing platform based on CRISPR/Cas13a-assisted hyperbranched rolling circle amplification (CRISPR/Cas13a-HRCA) for the detection of the AD-related biomarker miR-137. A duplex composed of Linear-Bio and a Cas13a linker strand was first immobilized on streptavidin-coated magnetic beads to construct magnetic probes. In the presence of miR-137, the linker strand was displaced and released into solution through strand exchange and magnetic separation. The released linker activated the CRISPR/Cas13a system via complementary pairing with crRNA, leading to cleavage of the UUU site within the topological DNA reporter (TDR). The cleaved TDR subsequently initiated the HRCA reaction in the presence of Vent DNA polymerase and the P2 probe, generating abundant double-stranded DNA products for fluorescence readout using SYBR Green I. By combining CRISPR/Cas13a amplification, magnetic separation, and label-free fluorescence detection, the platform produced a fluorescence response to miR-137 over 10 fM-100 nM, with an LOD and LOQ of 1.77 and 11.11 fM, respectively. Recoveries ranged from 99% to 106%, with RSDs of 2.2-2.6% in aCSF. Furthermore, the method successfully distinguished cerebrospinal fluid samples from AD patients and healthy individuals, demonstrating its potential for AD-related miRNA analysis.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.